(2S)-2-[(2-Methylpropan-2-yl)oxy]propan-1-ol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S)-2-[(2-Methylpropan-2-yl)oxy]propan-1-ol
• 化学式: C₇H₁₆O₂
• 分子量: 132.2
• InChiKey: GIWJLGYZXWVBDL-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• CHEMICAL PROCESS 632
  申请人：Butters Michael

  公开号：US20100210841A1

  公开（公告）日：2010-08-19

  A process for preparing pharmaceutically active compounds of formula (I) or a salt thereof wherein R 1 , n, m, R 3 , R 6 , X 1 , X 2 , X 3 and X 4 are as defined in the specification, is described. Novel intermediates are also described and claimed.

  提供制备具有以下结构的药用活性化合物（I）或其盐的方法 其中R1、n、m、R3、R6、X1、X2、X3和X4如规范中所定义。还描述和声明了新颖的中间体。
• HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES
  申请人：MCKERRECHER Darren

  公开号：US20090029905A1

  公开（公告）日：2009-01-29

  Compounds of formula (I) wherein R 1 , HET-1 and HET-2 are as described in the specification, and their salts and prodrugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.

  式(I)中，R1、HET-1和HET-2的化合物，以及它们的盐和前药，是葡萄糖激酶（GLK）的激活剂，因此在治疗例如2型糖尿病方面非常有用。本文还描述了制备式(I)化合物的过程。
• Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes
  申请人：Johnstone Craig

  公开号：US20090253676A1

  公开（公告）日：2009-10-08

  Compounds of Formula (I): wherein: R 1 is hydroxymethyl; R 2 is selected from —C(O)NR 4 R 5 , —SO 2 NR 4 R 5 , —S(O) p R 4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R 3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R 4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R 5 is hydrogen or (1-4C)alkyl; or R 4 and R 5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

  化学式（I）的化合物：其中：R1为羟甲基；R2选自- C（O）NR4R5，-SO2NR4R5，-S（O）pR4和HET-2; HET-1为5-或6-成员的，可选择性取代C-连接的杂芳基环；HET-2为4-，5-或6-成员的，C-或N-连接的可选择性取代杂环烷基环；R3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基；R4选自例如氢，可选择性取代的（1-4C）烷基和HET-2；R5为氢或（1-4C）烷基；或R4和R5与它们所附着的氮原子一起可以形成由HET-3定义的杂环烷基环系统；HET-3例如为可选择性取代的N-连接，4、5或6成员的，饱和或部分不饱和的杂环烷基环；p为（每次独立）0、1或2；m为0或1；n为0、1或2；但当m为0时，则n为1或2；或其盐、前药或溶剂。还描述了它们作为GLK激活剂的用途、含有它们的制药组合物以及它们的制备方法。
• Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
  申请人：McKerrecher Darren

  公开号：US20090105214A1

  公开（公告）日：2009-04-23

  Compounds of formula (I), wherein R 1 , R 4 , HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.

  式(I)的化合物中，其中R1、R4、HET-1和HET-2如规范所述，以及它们的盐和前药，是葡萄糖激酶(GLK)的激活剂，因此在治疗例如2型糖尿病方面是有用的。本文还描述了制备式(I)化合物的过程。
• HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS
  申请人：Caulkett Peter William Rodney

  公开号：US20090105263A1

  公开（公告）日：2009-04-23

  Compounds of Formula (I): wherein R 1 to R 11 , A and X 1 to X 3 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of Formula (I) are also described.

  公式（I）的化合物：其中R1到R11，A和X1到X3如说明书中所述，并且它们的盐，是葡萄糖激酶（GLK）的激活剂，因此在治疗例如二型糖尿病方面是有用的。还描述了制备公式（I）化合物的过程。